Michael Putman
YOU?
Author Swipe
View article: POS0133 THE FINDINGS FROM MOST RANDOMIZED CONTROLLED TRIALS OF GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS ARE FRAGILE
POS0133 THE FINDINGS FROM MOST RANDOMIZED CONTROLLED TRIALS OF GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS ARE FRAGILE Open
View article: The National Academies’ 2024 Diagnostic Criteria for Long <scp>COVID</scp>: Concerns That Could Affect the Rheumatology Community
The National Academies’ 2024 Diagnostic Criteria for Long <span>COVID</span>: Concerns That Could Affect the Rheumatology Community Open
View article: Positive and negative controls in rheumatology research
Positive and negative controls in rheumatology research Open
Positive and negative controls in rheumatology researchObservational research from large population databases may be affected by unmeasured confounding and time-related biases, such as immortal time bias.Modern causal inference practice ap…
View article: O40 Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the standard of care arms of randomized controlled trials
O40 Impact of glucocorticoid dose on complete response, serious infections, and mortality during the initial therapy of lupus nephritis: a systematic review and meta-analysis of the standard of care arms of randomized controlled trials Open
Objective The recent EULAR SLE guidelines recommend the use of reduced GC regimens (0.3–0.5 mg/kg) in the treatment of LN. However, as they acknowledged, this is not evidence-based. Our objective was to evaluate the effect of different GC …
View article: Data Fabrication in Rheumatology Randomized Controlled Trials: Evidence from a Systematic Review and Sampling Analysis
Data Fabrication in Rheumatology Randomized Controlled Trials: Evidence from a Systematic Review and Sampling Analysis Open
View article: Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies
Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies Open
Objective We aimed to evaluate the robustness of phase III randomised controlled trials (RCTs) for SLE and lupus nephritis (LN) using the fragility index (FI), the reverse FI (RFI) and the fragility quotient (FQ). Methods We searched for p…
View article: Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group
Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group Open
View article: Advocating for better trials in rheumatology
Advocating for better trials in rheumatology Open
Advocating for better trials in rheumatologyThe ADVOCATE trial, which compared the novel C5a inhibitor avacopan with placebo for patients with ANCAassociated vasculitis (AAV), was an important step forward in rheumatology [1].Substantive l…
View article: Incidence of <i>Pneumocystis Jiroveci</i> Pneumonia in Patients With <scp>ANCA‐Associated</scp> Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide
Incidence of <i>Pneumocystis Jiroveci</i> Pneumonia in Patients With <span>ANCA‐Associated</span> Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide Open
Objective This manuscript assesses the incidence of Pneumocystis jiroveci pneumonia (PJP) among patients receiving contemporary treatment regimens for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) and adverse events assoc…
View article: Erratum to “Social media for research discourse, dissemination, and collaboration in rheumatology”
Erratum to “Social media for research discourse, dissemination, and collaboration in rheumatology” Open
View article: Weighing the Risks and Benefits of <i>Pneumocystis Jirovecii</i> Pneumonia Prophylaxis in Rituximab Users
Weighing the Risks and Benefits of <i>Pneumocystis Jirovecii</i> Pneumonia Prophylaxis in Rituximab Users Open
Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author f…
View article: Social media for research discourse, dissemination, and collaboration in rheumatology
Social media for research discourse, dissemination, and collaboration in rheumatology Open
Social media has become an important venue for rheumatologists, patients, organizations, and other stakeholders to discuss recent research advances in diagnosis and management of rheumatic disorders. In this article, we describe the curren…
View article: Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey Open
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance …
View article: Comparative Efficacy Randomized Controlled Trials in Rheumatology Guidelines
Comparative Efficacy Randomized Controlled Trials in Rheumatology Guidelines Open
Background Comparative efficacy randomized controlled trials (RCTs) compare two active interventions in a head‐to‐head design. They are useful for informing clinical practice guidelines, but the degree to which such trials inform clinical …
View article: COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN)
COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN) Open
Objective Patients with systemic lupus erythematosus (SLE) are at higher risk of poor outcomes from coronavirus disease 2019 (COVID-19). The vaccination rate among such patients is unknown. We aimed to assess COVID-19 vaccine uptake among …
View article: Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals
Any Given Monday: Association Between Desk Rejections and Weekend Manuscript Submissions to Rheumatology Journals Open
View article: Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey
Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey Open
Objective To assess rheumatology clinicians’ perceptions of telemedicine as well as their experiences before and during the COVID-19 pandemic. Methods We conducted a cross-sectional online survey and collected responses from rheumatology c…
View article: Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey Open
Objective To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD). Methods An international study was conducted from 2 April to 16 August 2021, using…
View article: COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey Open
View article: Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology Open
View article: Where do we go after GiACTA?
Where do we go after GiACTA? Open
View article: Association between Biologic Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis
Association between Biologic Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis Open
View article: The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey
The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey Open
Objective The aim was to evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic on the clinical experiences, research opportunities and well-being of rheumatology trainees. Methods A voluntary, anonymous, Web-based survey …
View article: Is There a Role for Pneumocystis Jiroveci Pneumonia Prophylaxis in Giant Cell Arteritis or Polymyalgia Rheumatica?
Is There a Role for Pneumocystis Jiroveci Pneumonia Prophylaxis in Giant Cell Arteritis or Polymyalgia Rheumatica? Open
View article: Dr. Conway et al reply
Dr. Conway et al reply Open
We thank Sauret et al1 for their interest in our systematic literature review that explored potential diagnostic confusion between giant cell arteritis (GCA) and the coronavirus disease 2019 (COVID-19). This was a particularly important co…
View article: Benchmarking tocilizumab use for giant cell arteritis
Benchmarking tocilizumab use for giant cell arteritis Open
View article: <scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis
<span>SARS</span>–<span>CoV</span>‐2 Infection and <span>COVID</span>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis Open
Objective The relative risk of SARS–CoV‐2 infection and COVID‐19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of …
View article: Rapid Adoption of Telemedicine in Rheumatology Care During the <scp>COVID</scp>‐19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees
Rapid Adoption of Telemedicine in Rheumatology Care During the <span>COVID</span>‐19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees Open
Objective To evaluate the impact of telemedicine use during the coronavirus disease 2019 (COVID‐19) pandemic on rheumatology trainees. Methods A voluntary, anonymous, web‐based survey was administered in English, Spanish, or French from Au…
View article: Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study Open
View article: Dr. Conway et al reply
Dr. Conway et al reply Open
We thank Sauret et al1 for their interest in our systematic literature review that explored potential diagnostic confusion between giant cell arteritis (GCA) and the coronavirus disease 2019 (COVID-19). This was a particularly i…